
Collage photo of Elias K. Mai and Malin Hultcrantz
Sep 20, 2024, 14:26
Malin Hultcrantz: Colesevelam for treatment of lenalidomide associated diarrhea
Elias K. Mai, Board Certified Specialist in Internal Medicine, Hematology and Oncology at University Hospital Heidelberg, shared a post by Malin Hultcrantz, Associate Attending Physician, Assistant Professor at MSK Cancer Center, on X, adding:
“Practice informing study on supportive care in MM by Malin Hultcrantz and colleagues. Congratulations!
I use it in my daily practice for many years now, but back-up from trials like this is essential!”
Quoting Malin Hultcrantz’s post:
“Colesevelam is highly effective and safe for treatment of lenalidomide associated diarrhea:
– Phase 2 trial, 25 patients
– 88% improved diarrhea
– 68% complete resolution
– No effect on lenalidomide PK”
Source: Elias K. Mai/X and Malin Hultcrantz/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 21, 2025, 14:27
Feb 21, 2025, 14:13
Feb 21, 2025, 13:29
Feb 21, 2025, 13:07
Feb 21, 2025, 13:06
Feb 21, 2025, 13:03